Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1364-1374

  Sturm, Isrid ^a   Köhne, Claus Henning ^a   Wolff, Gerhard ^a   Petrowsky, Henrik ^a   Hillebrand, Timo ^a   Hauptmann, Steffen ^a   Lorenz, Matthias ^a   Dörken, Bernd ^a   Daniel, Peter T ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LIVER METASTASIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0344348993     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1364     Document Type: Article

References (53)

1. Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985
2. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349:254-256, 1991
3. Tsujimoto Y: Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 4:1331-1336, 1989
4. Reed JC, Miyashita T, Takayama S, et al: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23-32, 1996
5. Minn AJ, Rudin CM, Boise LH, et al: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903-1910, 1995
6. Bargou RC, Daniel PT, Mapara MY, et al: Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60:854-859, 1995
7. Bargou RC, Wagener C, Bommert K, et al: Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 97:2651-2659, 1996
8. Wagener C, Bargou RC, Daniel PT, et al: Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67:138-141, 1996
9. Yin C, Knudson CM, Korsmeyer SJ, et al: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385:637-640, 1997
10. Krajewski S, Blomqvist C, Franssila K, et al: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995
11. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15:938-946, 1997
12. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients - Association Francaise de Chirurgie. Cancer 77:1254-1262, 1996
13. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
14. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993
15. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonie carcinogenesis. Nature 363:558-561, 1993
16. Perucho M: Cancer of the microsatellite mutator phenotype. Biol Chem 377:675-684, 1996
17. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969, 1997
18. Yamamoto H, Sawai H, Weber TK, et al: Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res 58:997-1003, 1998
19. Yagi OK, Akiyama Y, Nomizu T, et al: Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. Gastroenterology 114:268-274, 1998
20. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993
21. Weyrer K, Feichtinger H, Haun M, et al: p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 74:279-289, 1996
22. Simms LA, Radford-Smith G, Biden KG, et al: Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene 17:2003-2008, 1998
23. Tai YT, Lee S, Niloff E, et al: BAX protein expression and clinical outcome in epithelial ovarian cancer [see comments]. J Clin Oncol 16:2583-2590, 1998
24. Gascoyne RD, Krajewska M, Krajewski S, et al: Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:3173-3178, 1997
25. Zha H, Reed JC: Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 272:31482-31488, 1997
26. Xiang J, Chao DT, Korsmeyer SJ: BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A 93:14559-14563, 1996
27. Schlesinger PH, Gross A, Yin XM, et al: Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci U S A 94:11357-11362, 1997
28. Pastorino JG, Chen ST, Tafani M, et al: The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273:7770-7775, 1998
29. Jürgensmeier JM, Xie ZH, Deveraux Q, et al: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 95:4997-5002, 1998
30. Decaudin D, Marzo I, Brenner C, et al: Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy. Int J Oncol 12:141-152, 1998
31. Liu X, Zou H, Slaughter C, et al: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175-184, 1997
32. Zou H, Henzel WJ, Liu X, et al: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413, 1997
33. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
34. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
35. Hasegawa H, Ueda M, Furukawa K, et al: p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. Int J Cancer 64:47-51, 1995
36. Wang A, Yoshimi N, Ino N, et al: WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 123:118-123, 1997
37. Pricolo VE, Finkelstein SD, Hansen K, et al: Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 132:371-374, 1997
38. Borresen-Dale AL, Lothe RA, Meling GI, et al: TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210, 1998
39. Hamelin R, Laurent PP, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106:42-48, 1994
40. Remvikos Y, Tominaga O, Hammel P, et al: Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66:758-764, 1992
41. Yamaguchi A, Nakagawara G, Kurosaka Y, et al: p53 immunoreaction in endoscopie biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399-402, 1993
42. Maeda K, Chung YS, Kang SM, et al: Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74:310-315, 1997
43. Scott N, Sagar P, Stewart J, et al: p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br J Cancer 63:317-319, 1991
44. Paradiso A, Rabinovich M, Vallejo C, et al: p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis. Int J Cancer 69:437-441, 1996
45. Poller DN, Baxter KJ, Shepherd NA: p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer? Br J Cancer 75:87-93, 1997
46. Belluco C, Guillem JG, Kemeny N, et al: p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696-2701, 1996
47. Kastrinakis WV, Ramchurren N, Rieger KM, et al: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:641-652, 1995
48. El-Deiry W, Harper JW, O'Connor PM, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994
49. Ogretmen B, Safa AR: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 14:499-506, 1997
50. Soong R, Robbins PD, Dix BR, et al: Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27:1050-1505, 1996
51. Dix B, Robbins P, Carrello S, et al: Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70:585-590, 1994
52. Cripps KJ, Purdie CA, Carder PJ, et al: A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 9:2739-2743, 1994
53. Visscher DW, Sarkar FH, Shimoyama RK, et al: Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol 5:187-193, 1996